Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Exact Sciences Corp (EXAS:NASDAQ), powered by AI.
Exact Sciences Corp is currently trading at $104.91. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Exact Sciences Corp on Alpha Lenz.
Exact Sciences Corp's P/E ratio is -95.2.
“Exact Sciences Corp trades at a P/E of -95.2 (undervalued) with modest ROE of -8.7%. 3Y revenue CAGR of 15.9% highlights clear growth momentum.”
Ask for details →Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.
“Exact Sciences Corp trades at a P/E of -95.2 (undervalued) with modest ROE of -8.7%. 3Y revenue CAGR of 15.9% highlights clear growth momentum.”
Ask for details →Exact Sciences Corp (ticker: EXAS) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 6,900 employees. Market cap is $19.8B.
The current price is $104.91 with a P/E ratio of -95.19x and P/B of 8.24x.
ROE is -8.66% and operating margin is -6.13%. Annual revenue is $3.2B.